Summary
This phase I, open-label, dose-escalation study assessed the maximum-tolerated dose, safety, pharmacokinetics, and preliminary antitumor activity of pazopanib plus lapatinib combination therapy in patients with solid tumors. Patients were to take pazopanib and lapatinib orally once daily in a fasting condition. During the escalation phase, pazopanib and lapatinib doses were escalated in serial patient cohorts, and a limited blood sampling scheme was applied for pharmacokinetic evaluation. In the expansion phase, potential pharmacokinetic interaction between pazopanib and lapatinib was evaluated more extensively. Seventy-five patients were treated. Multiple dosing levels were studied, combining pazopanib up to 800 mg/day with lapatinib up to 1,500 mg/day. Dose-limiting toxicities observed included grade 3 neutropenia, fatigue, asymptomatic decline in left ventricular ejection fraction, diarrhea, and liver enzyme elevations. The most common drug-related adverse events were diarrhea, nausea, anorexia, fatigue, vomiting, rash, hair depigmentation, and hypertension. The dose recommended for further evaluation was pazopanib 800 mg plus lapatinib 1,500 mg (paz-800/lap-1500). No clinically significant drug-drug interaction was observed at the paz-400/lap-1000 level. However, at paz-800/lap-1500, an increase in both the AUC0-t and Cmax of pazopanib was observed. Four partial responses were observed in patients with renal cancer (n = 2), giant-cell tumor of the bone (n = 1), and thyroid cancer (n = 1). Stable disease for ≥18 weeks was seen in 12 patients. Pazopanib and lapatinib can be administered in combination at their respective single-agent doses with an acceptable safety profile. Further evaluation of the combination will be pursued, exploring both paz-800/lap-1500 and paz-400/lap-1000.
Similar content being viewed by others
References
Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29:15–18
Jones RG, Thompson CB (2009) Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23:537–548
Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676
Gasparini G (2000) Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5(Suppl 1):37–44
Paley PJ, Staskus KA, Gebhard K et al (1997) Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 80:98–106
Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995–4004
Phillips RJ, Mestas J, Gharaee-Kermani M et al (2005) Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 280:22473–22481
Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK (2002) Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416:279–280
Perrotte P, Matsumoto T, Inoue K et al (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5:257–265
Petit AM, Rak J, Hung MC et al (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523–1530
Viloria-Petit A, Crombet T, Jothy S et al (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61:5090–5101
VOTRIENT (pazopanib) tablets [prescribing information]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022465s002lbl.pdf. Accessed June 8, 2012
Gomez HL, Doval DC, Chavez MA et al (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26:2999–3005
TYKERB (lapatinib) tablets [prescribing information]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf. Accessed June 6, 2012
GlaxoSmithKline Study of safety and tolerability of GW786034 given with lapatinib in cancer patients. http://www.clinicaltrials.gov/ct2/show/NCT00158782?term=lapatinib%2C+pazopanib%2C+phase+i&rank=4. Accessed June 20, 2012
Goh BC, Reddy NJ, Dandamudi UB et al (2010) An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 88:652–659
van Erp NP, Gelderblom H, Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692–706
National Cancer Institute (2006) Common terminology criteria for adverse events v3.0 (CTCAE). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed June 8, 2012
European Organization for Research and Treatment of Cancer, National Cancer Institute, National Cancer Institute of Canada Clinical Trials Group Response Evaluation Criteria In Solid Tumors, Version 1.1 (published 2009). http://www.recist.com/. Accessed June 8, 2012
Hsieh S, Tobien T, Koch K, Dunn J (2004) Increasing throughput of parallel on-line extraction liquid chromatography/electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development. Rapid Commun Mass Spectrom 18:285–292
Blackwell KL, Burstein HJ, Storniolo AM et al (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28:1124–1130
Perry J, Ghazaly E, Kitromilidou C, McGrowder EH, Joel S, Powles T (2010) A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP. Mol Cancer Ther 9:3322–3329
Ozvegy-Laczka C, Hegedus T, Varady G et al (2004) High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 65:1485–1495
Hegedus C, Ozvegy-Laczka C, Apati A et al (2009) Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 158:1153–1164
Mi Y, Lou L (2007) ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. Br J Cancer 97:934–940
Zheng LS, Wang F, Li YH et al (2009) Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One 4:e5172
Booth CM, Calvert AH, Giaccone G, Lobbezoo MW, Seymour LK, Eisenhauer EA (2008) Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT). Eur J Cancer 44:19–24
Monk BJ, Mas Lopez L, Zarba JJ et al (2010) Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol 28:3562–3569
Slamon D, Gomez HL, Kabbinavar FF et al. (2008) Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J Clin Oncol 26(suppl;15s):abstr 1016
Slamon D, Stemmer SM, Johnston S et al. (2008) Phase 2 study of dual VEGF/HER2 blockade with pazopanib + lapatinib in patients with first-line HER2-positive advanced or metastatic breast cancer. Presented at the 31st Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 10–14, Abstract 4114
GlaxoSmithKline Pazopanib plus lapatinib compared to lapatinib alone in subjects with advanced or metastatic breast cancer. http://www.clinicaltrials.gov/ct2/show/NCT00347919?term=00347919&rank=1. Accessed July 2, 2012
GlaxoSmithKline Pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma (VEG102857). http://www.clinicaltrials.gov/ct2/show/NCT00350727?term=00350727&rank=1. Accessed July 2, 2012
GlaxoSmithKline Pazopanib plus lapatinib compared to lapatinib alone and pazopanib alone in subjects with metastatic cervical cancer. http://www.clinicaltrials.gov/ct2/show/NCT00430781?term=00430781&rank=1. Accessed July 2, 2012
Acknowledgments
We thank the patients and their families who made this study possible. We thank Mohammed Dar, MD, of GlaxoSmithKline for providing input in the analysis of data and authoring the CSR. We thank Tamalette Loh, PhD, of ProEd Communications, Inc., for her editorial assistance in preparation of this manuscript. Financial support for this study and medical editorial assistance was provided by GlaxoSmithKline Pharmaceuticals, Research Triangle Park, NC.
Ethical standards
This study complied with the laws of the countries in which it was conducted (United States and The Netherlands), and the study was approved by the respective institutional ethics committees.
Conflict of interest
M.J.A. de Jonge, P. Hamberg, and S. Savage report no potential conflict of interest. J. Verweij reports honoraria from and a consultant/advisor role with GlaxoSmithKline. H.I. Hurwitz has received research funding from GlaxoSmithKline. A.B. Suttle, J. Hodge, T. Arumugham, and L.N. Pandite are GlaxoSmithKline employees and stockholders.
Author information
Authors and Affiliations
Corresponding author
Additional information
Previous publication
Portions of these data were presented at the 2006 ASCO Annual Meeting and published in J Clin Oncol 2006;24:18s(suppl; abstr 3088).
Rights and permissions
About this article
Cite this article
de Jonge, M.J.A., Hamberg, P., Verweij, J. et al. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs 31, 751–759 (2013). https://doi.org/10.1007/s10637-012-9885-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-012-9885-8